GLP− 1 receptor agonists for the treatment of obesity: Role as a promising approach
JY Wang, QW Wang, XY Yang, W Yang… - Frontiers in …, 2023 - frontiersin.org
Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …
by genetic, environmental and other factors. In recent years, there has been an increase in …
[HTML][HTML] Anxiety, depression, and the microbiome: a role for gut peptides
The complex bidirectional communication between the gut and the brain is finely
orchestrated by different systems, including the endocrine, immune, autonomic, and enteric …
orchestrated by different systems, including the endocrine, immune, autonomic, and enteric …
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review
N Reich, C Hölscher - Frontiers in neuroscience, 2022 - frontiersin.org
Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
A Secher, J Jelsing, AF Baquero… - The Journal of …, 2014 - Am Soc Clin Investig
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2
diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully …
diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully …
[HTML][HTML] Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
Abstract Objective Although Glucagon-like peptide 1 is a key regulator of energy metabolism
and food intake, the precise location of GLP-1 receptors and the physiological relevance of …
and food intake, the precise location of GLP-1 receptors and the physiological relevance of …
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
C Hölscher - Expert opinion on investigational drugs, 2020 - Taylor & Francis
Introduction: This review evaluates the novel strategy of treating Alzheimer's and Parkinson's
disease (AD and PD) withdrugs that initially have been developed to treat type 2 diabetes …
disease (AD and PD) withdrugs that initially have been developed to treat type 2 diabetes …
2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans
Objective: Dietary fat is thought to stimulate release of incretin hormones via activation of
fatty acid receptors in the intestine. However, dietary fat (triacylglycerol) is digested to 2 …
fatty acid receptors in the intestine. However, dietary fat (triacylglycerol) is digested to 2 …
Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity
DB Maselli, M Camilleri - Diabetes: from Research to Clinical Practice …, 2021 - Springer
The processing of proglucagon in intestinal L cells results in the formation of glucagon, GLP-
1, and GLP-2. The GLP-1 molecule becomes active through the effect of proconvertase 1 …
1, and GLP-2. The GLP-1 molecule becomes active through the effect of proconvertase 1 …
Proglucagon-derived peptides as therapeutics
Initially discovered as an impurity in insulin preparations, our understanding of the
hyperglycaemic hormone glucagon has evolved markedly over subsequent decades. With …
hyperglycaemic hormone glucagon has evolved markedly over subsequent decades. With …
GLP-1 mimetics and cognition
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic drugs
that improve the glycaemia via several molecular pathways. Recent evidence suggest that …
that improve the glycaemia via several molecular pathways. Recent evidence suggest that …